Top

Published in:

01-02-2001 | Commentary

E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer?

Author: Anne-Marie Cleton-Jansen

Published in: Breast Cancer Research | Issue 1/2001

Abstract

Loss of heterozygosity at the long arm of chromosome 16 is one of the most frequent genetic events in breast cancer. In the search for tumour suppressor genes that are the target of loss of heterozygosity at 16q, the E-cadherin gene CDH1 was unveiled by the identification of truncating mutations in the retained copy. However, only lobular tumours showed E-cadherin mutations. Whereas investigations are still devoted to finding the target genes in the more frequent ductal breast cancers, other studies suspect the E-cadherin gene to also be the target in this tumour type. The present article discusses the plausibility of those two lines of thought.

Vleminckx K, Kemler R: Cadherins and tissue formation: integrating adhesion and signaling. Bioessays. 1999, 21: 211-220. 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.0.CO;2-P.CrossRefPubMed

Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hiro-hashi S: Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA. 1995, 92: 7416-7419.CrossRefPubMedPubMedCentral

Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB: E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995, 55: 5195-5199.PubMed

Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia DH: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000, 2: 84-89. 10.1038/35000034.CrossRefPubMed

Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D, Van Roy F: The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell. 2001, 7: 1267-1278. 10.1016/S1097-2765(01)00260-X.CrossRefPubMed

Tan C, Costello P, Sanghera J, Dominguez D, Baulida J, De Herreros AG, Dedhar S: Inhibition of integrin linked kinase (ILK) suppresses beta-catenin–Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC-/- human colon carcinoma cells. Oncogene. 2001, 20: 133-140. 10.1038/sj.onc.1204052.CrossRefPubMed

Berx G, Becker KF, Hofler H, Van Roy F: Mutations of the human E-cadherin (CDH1) gene. Hum Mutat. 1998, 12: 226-237. 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D.CrossRefPubMed

Berx G, Cleton-Jansen AM, Strumane K, De Leeuw WJF, Nollet F, Van Roy F, Cornelisse C: E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 1996, 13: 1919-1925.PubMed

Berx G, Cleton-Jansen AM, Nollet F, De Leeuw WJF, Van de Vijver MJ, Cornelisse C, Van Roy F: E-cadherin is a tumour invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 1995, 14: 6107-6115.PubMedPubMedCentral

10.

Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet. 1999, 21: 163-167. 10.1038/5947.CrossRefPubMed

11.

Cleton-Jansen AM, Callen DF, Seshadri R, Goldup S, McCallum B, Crawford J, Powell JA, Settasatian C, van Beerendonk H, Moer-land EW, Smit VT, Harris WH, Millis R, Morgan NV, Barnes D, Mathew CG, Cornelisse CJ: Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions. Cancer Res. 2001, 61: 1171-1177.PubMed

12.

Tischfield JA: Loss of heterozygosity or: how I learned to stop worrying and love mitotic recombination. Am J Hum Genet. 1997, 61: 995-999. 10.1086/301617.CrossRefPubMedPubMedCentral

13.

Devilee P, Cleton-Jansen AM, Cornelisse CJ: Ever since Knudson. Trends Genet. 2001, 17: 569-573. 10.1016/S0168-9525(01)02416-7.CrossRefPubMed

14.

Beavon IR: Regulation of E-cadherin: does hypoxia initiate the metastatic cascade?. Mol Pathol. 1999, 52: 179-188.CrossRefPubMedPubMedCentral

15.

De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov S, Van Roy F, Cornelisse CJ, Cleton-Jansen AM: Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol. 1997, 183: 404-411. 10.1002/(SICI)1096-9896(199712)183:4<404::AID-PATH1148>3.0.CO;2-9.CrossRefPubMed

16.

Vos CB, Cleton-Jansen AM, Berx G, De Leeuw WJ, ter Haar NT, Van Roy F, Cornelisse CJ, Peterse JL, Van de Vijver MJ: E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer. 1997, 76: 1131-1133.CrossRefPubMedPubMedCentral

17.

Vos CBJ, ter Haar NT, Rosenberg C, Peterse JL, Cleton-Jansen A-M, Cornelisse CJ, Van de Vijver MJ: Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histological type. Br J Cancer. 1999, 81: 1410-1418. 10.1038/sj.bjc.6693372.CrossRefPubMedPubMedCentral

18.

Vleminckx K, Vakaet L, Mareel M, Fiers W, Van Roy F: Genetic manipulations of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell. 1991, 66: 107-119.CrossRefPubMed

19.

Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998, 392: 190-193. 10.1038/32433.CrossRefPubMed

20.

Birchmeier W, Behrens J: Cadherin expression in carcinomas: Role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta. 1994, 1198: 11-26. 10.1016/0304-419X(94)90003-5.PubMed

21.

Lakhani SR, Collins N, Sloane JP, Stratton MR: Loss of heterozy-gosity in lobular carcinoma in situ of the breast. J Clin Pathol. 1995, 48M: M74-M78.

22.

Lakhani SR: The transition from hyperplasia to invasive carcinoma of the breast. J Pathol. 1999, 187: 272-278. 10.1002/(SICI)1096-9896(199902)187:3<272::AID-PATH265>3.0.CO;2-2.CrossRefPubMed

23.

Roylance R, Gorman P, Harris W, Liebmann R, Barnes D, Hanby A, Sheer D: Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res. 1999, 59: 1433-1436.PubMed

24.

Buerger H, Simon R, Schafer KL, Diallo R, Littmann R, Poremba C, Van Diest PJ, Dockhorn-Dworniczak B, Bocker W: Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast. Mol Pathol. 2000, 53: 118-121. 10.1136/mp.53.3.118.CrossRefPubMedPubMedCentral

25.

Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE: E-cadherin germline mutations in familial gastric cancer. Nature. 1998, 392: 402-405. 10.1038/32918.CrossRefPubMed

26.

Richards FM, McKee SA, Rajpar MH, Cole TR, Evans DG, Jankowski JA, McKeown C, Sanders DS, Maher ER: Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet. 1999, 8: 607-610. 10.1093/hmg/8.4.607.CrossRefPubMed

27.

Rahman N, Stone JG, Coleman G, Gusterson B, Seal S, Marossy A, Lakhani SR, Ward A, Nash A, McKinna A, A'Hern R, Stratton MR, Houlston RS: Lobular carcinoma in situ of the breast is not caused by constitutional mutations in the E-cadherin gene. Br J Cancer. 2000, 82: 568-570. 10.1054/bjoc.1999.0965.CrossRefPubMedPubMedCentral

28.

Grady WM, Willis J, Guilford PJ, Dunbier AK, Toro TT, Lynch H, Wiesner G, Ferguson K, Eng C, Park JG, Kim SJ, Markowitz S: Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet. 2000, 26: 16-17. 10.1038/79120.CrossRefPubMed

Title: E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer?
Author: Anne-Marie Cleton-Jansen
Publication date: 01-02-2001
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 1/2001
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr416

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2001

Lysosomal Enzyme-Induced Cell Death in MCF7 and Mammary Gland Cells.

Primary chemotherapy with CEF-infu

Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models

What centrosomes can teach us about tumor progression

Mammographic breast density as a biomarker of effects of isoflavones on the female breast

bcl-2: a convergence point for multiple signal transduction pathways that influence cell survival?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer